Natera Reports Second Quarter 2021 Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Natera Inc (NASDAQ: NTRA)Cassava Sciences Inc
First, we have the clinical-stage biopharmaceutical company, Cassava. The company focuses on developing drugs for the treatment of nervous system disorders. Cassava is currently in focus due to the spotlight on the treatment of Alzheimerâs disease. This comes after Biogen Inc (NASDAQ: BIIB) received an accelerated FDA approval for its drug ADUHELMâ¢. So, investors appear to be optimistic that Cassavaâs simufilam and SavaDx may benefit from this development. Â
Simufilam is Cassavaâs lead drug candidate to treat Alzheimerâs disease while SavaDx is an investigational diagnostic candidate to detect Alzheimerâs. The company will be presenting its results of an interim analysis on safety and cognition for the first 50 subjects to complete 9 months of open-label drug treatment. These data will be presented at the 2021 Alzheimerâs Association International Conference (AAIC) in Denver scheduled for 26th to
/PRNewswire/ The Liquid Biopsy for Cancer Diagnostics Competitive Landscape and Pipeline report is expected to rise due to an increased prevalence rate of.
Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
What happened
Shares of
Guardant Health (NASDAQ:GH) were rising 4.7% higher as of 10:54 a.m. EDT on Thursday. The gain came after the company announced that its Guardant Reveal blood test received Clinical Laboratory Evaluation Program (CLEP) approval from the New York State Department of Health in detecting and monitoring residual disease in patients with early-stage cancer.
So what
The win in New York marked an important milestone for Guardant Health. The company launched its Guardant Reveal product earlier this year. CLEP approval will allow oncologists in the Empire State to use the liquid biopsy test in two ways: identifying high-risk patients with colo